Data transparency initiatives 'could deter industry investment'
This article was originally published in SRA
Executive Summary
The pharmaceutical industry fears that early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But regulators say investors should welcome the initiatives because they will bring greater efficiency to drug development. Sue Sutter reports on the debate from the US Biotechnology Industry Organization's annual convention in Philadelphia.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.